

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

9-839574

#13

Document AO2  
Appl. No. 09/839,574

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>6</sup>:

A61K 31/00

A1

(11) International Publication Number:

WO 95/10265

(43) International Publication Date:

20 April 1995 (20.04.95)

(21) International Application Number: PCT/US94/11594

(22) International Filing Date: 12 October 1994 (12.10.94)

(30) Priority Data:

138,271

15 October 1993 (15.10.93)

US

(71) Applicant: CYTRX CORPORATION [US/US]; 150 Technology Parkway, Norcross, GA 30092 (US).

(72) Inventors: EMANUELE, R., Martin; 5320 North Hillbrook Trace, Alpharetta, GA 30202 (US). ALLAUDEEN, Hameedsulthan, S.; 810 Buttercup Trace, Alpharetta, GA 30202 (US). KOUSOULAS, Konstantin, G.; 10543 N. Myrtle Lake Avenue, Baton Rouge, LA 70810 (US).

(74) Agents: JOHNSON, James, Dean et al.; Jones &amp; Askew, 37th floor, 191 Peachtree Street, N.E., Atlanta, GA 30303-1769 (US).

(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

## Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: THERAPEUTIC DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF

## (57) Abstract

The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a therapeutic delivery composition effective for treating a disease state comprising an administerable admixture of an effective amount of a therapeutic compound capable of altering nucleic acid sequence function and an effective amount of a surface active nonionic block copolymer having the following general formula:  $\text{HO}(\text{C}_2\text{H}_4\text{O})_b(\text{C}_3\text{H}_5\text{O})_a(\text{C}_2\text{H}_4\text{O})_b\text{H}$  wherein  $a$  is an integer such that the hydrophobe represented by  $(\text{C}_3\text{H}_5\text{O})_a$  has a molecular weight of approximately 750 and approximately 15,000, preferably between approximately 2,250 and approximately 15,000, more preferably between approximately 3,250 and approximately 15,000, and  $b$  is an integer such that the hydrophilic portion represented by  $(\text{C}_2\text{H}_4\text{O})_b$  constitutes approximately 1 % to approximately 50 % by weight of the compound, preferably approximately 5 % to approximately 20 %.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

5

## THERAPEUTIC DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF

10

### Technical Field

15 The present invention relates to therapeutic delivery compounds and to compositions comprising therapeutic delivery compounds that kill or suppress the growth of bacteria, viruses, fungi and protozoa, and methods of use thereof. The compounds, compositions and methods are effective for the delivery of drugs and other compounds to the interior of cells and for controlling intracellular organisms.

20

### Background of the Invention

25 Many new and potentially useful technologies are being developed which may form the basis of future medical cures and therapies. Examples of such technologies include, gene replacement, antisense gene therapy, triplex gene therapy and ribozyme-based therapy. However, to be successful, these technologies require effective means for the delivery of the therapeutic agent across cellular, nuclear and microorganismal membranes.

30

35 The recent advent of technology, and advances in our ability to understand the structure and function of many genes makes it possible to selectively turn off or modify the activity of a given gene. Alteration of gene activity can be accomplished many ways. For example, oligonucleotides that are complementary to certain gene messages or viral sequences, known as "antisense" compounds, have been shown to have an

- 2 -

inhibitory effect against viruses. By creating an antisense compound that hybridizes with the targeted RNA message of cells or viruses the translation of the message into protein can be interrupted or prevented. In this fashion gene activity can be modulated.

The ability to deactivate specific genes provides great therapeutic benefits. For example, it is theoretically possible to fight viral diseases with antisense RNA and DNA molecules that seek out and destroy viral gene products. In tissue culture, antisense oligonucleotides have inhibited infections by herpes-viruses, influenza viruses and the human immunodeficiency virus that causes AIDS. It may also be possible to target antisense oligonucleotides against mutated oncogenes. Antisense technology also holds the potential for regulating growth and development. However, in order for the gene therapy to work, antisense therapeutic compounds must be delivered across cellular plasma membranes to the cytosol.

Gene activity is also modified using sense DNA in a technique known as gene therapy. Defective genes are replaced or supplemented by the administration of "good" or normal genes that are not subject to the defect. The administered normal genes which insert into a chromosome, or may be present in extracellular DNA, produce normal RNA, which in turn leads to normal gene product. In this fashion gene defects and deficiencies in the production of gene product may be corrected. Still further gene therapy has the potential to augment the normal genetic complement of a cell. For example, it has been proposed that one way to combat HIV is to introduce into an infected person's T cells a gene that makes the cells resistant to HIV infection. This form of gene therapy is sometimes called "intracellular immunization." Genetic material such as polynucleotides may be administered to a mammal to elicit an immune response against the gene product of the administered nucleic acid sequence. Such gene vaccines elicit an immune response in the following manner. First, the

- 3 -

nucleic acid sequence is administered to a human or animal. Next, the administered sequence is expressed to form gene product within the human or animal. The gene product inside the human or animal is recognized as foreign material and the immune system of the human or animal mounts an immunological response against the gene product. However, this approach currently is not feasible due to a lack of effective gene delivery systems that facilitate the delivery of genetic material across both cellular and nuclear membranes.

Finally, gene therapy may be used as a method of delivering drugs *in vivo*. For example, if genes that code for therapeutic compounds can be delivered to endothelial cells, the gene products would have facilitated access to the blood stream. Currently, genes are delivered to cells *ex vivo* and then reintroduced to the animal.

Retroviral vectors can be used to deliver genes *ex vivo* to isolated cells, which are then infused back into the patient. However, retroviral vectors have some drawbacks, such as being able to deliver genes only to dividing cells, random integration of the gene to be delivered, potentially causing unwanted genetic alterations, and possibly reverting back to an infectious wild-type retroviral form. Another drawback of antisense gene therapy is that it is effective at the messenger RNA level, which means that antisense oligonucleotides must be introduced in a quantity to interact with all or a substantial number of the mRNA in the cytosol, and that such treatment is only effective during active synthesis of mRNA. Further, the oligonucleotides must be maintained at this high quantity level throughout mRNA synthesis to be effective over time.

Newly developed "triplex DNA" technology represents an improvement in gene regulation. Triplex DNA technology utilizes oligonucleotides and compounds that specifically bind to particular regions of duplex DNA, thereby inactivating the targeted gene. An advantage of triplex DNA

- 4 -

5 technology is that only a single copy of the oligonucleotide or compound is required to alter gene expression because the binding is at the DNA level, not the mRNA level. A drawback of triplex DNA technology, however, is that the oligonucleotide or compound must pass through not only the cellular membrane, but also the microbial membrane in the case of treating microbial infections, or the nuclear membrane in the case of altering eukaryotic gene function or expression of foreign DNA integrated into chromosomal DNA.

10 Another emerging technology relates to the therapeutic use of ribozymes for the treatment of genetic disorders. Ribozymes are catalytic RNA molecules that consist of a hybridizing region and an enzymatic region. Ribozymes may in the future be engineered so as to specifically bind to a targeted region of nucleic acid sequence and cut or otherwise enzymatically modify the sequence so as to alter its expression or translation into gene product.

15 There is a great need, therefore, for improved delivery systems for genetic material such as genes, polynucleotides, and antisense oligonucleotides that can be used in gene therapy. More specifically, there is a need for non-toxic compositions having surfactant properties that can facilitate the transport of genetic compounds and other drugs and therapeutic compounds across cellular membranes.

20 There is a particularly urgent need for an effective treatment for Acquired Immune Deficiency Syndrome, or AIDS, a disease thought to be caused by a human retrovirus, the Human T Lymphotropic Virus III (HTLV-III) which is also called human immunodeficiency virus or HIV. Like other retroviruses, HIV has ribonucleic acid, or RNA, as its genetic material. When the virus enters the host cell, a viral enzyme called reverse transcriptase exploits the viral RNA as a template to assemble a corresponding molecule of DNA. The DNA travels through the cell nucleus and inserts itself among the host chromosomes, where it provides the basis for viral replication.

25  
30  
35

- 5 -

5 In the case of HIV, the host cell is often a T4 lymphocyte, a white blood cell that has a central and regulatory role in the immune system. Once it is inside a T4 cell, the virus may remain latent until the lymphocyte is immunologically stimulated by a secondary infection. Then the virus reproducing itself rapidly killing or rendering ineffective the host cell. The resulting depletion of the T4 cells, and loss of activity leaves the patient vulnerable to "opportunistic" infections by an agent that would not normally harm a healthy person. The virus damages the host by many other mechanisms as well.

10 Many therapies against AIDS infection that are currently being investigated. Several of these therapies under investigation are based on interrupting the reverse transcriptase as it assembles the viral DNA destined to become the virus. The drugs used for this purpose are chemical analogs of the nucleic acids that form the subunits of DNA. When the analog is supplied to an infected cell, reverse transcriptase will incorporate it into a growing DNA chain. Because the analog lacks the correct attachment point for the next subunit, however, the chain is terminated. The truncated DNA cannot integrate itself into the host chromosomes or provide the basis for viral replication, and so the spread of the infection is halted. One of the compounds that is thought to act by mimicking a nucleotide is azidothymidine, or AZT. However, AZT is known to have serious side effects and its efficacy in mitigating the AIDS disease has been questioned. The efficacy of AZT and other antiviral and antimicrobial drugs could be increased if improved means and methods for delivering therapeutic agents to the site of infection were available.


### 30 Summary of the Invention

35 The present invention includes a method of delivering therapeutic drugs to a human or animal for treating disease states such as, but not limited to, bacterial infection and infections caused by HIV and other DNA and RNA viruses.

- 6 -

The present invention relates particularly to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences.

5 The present invention comprises a therapeutic delivery composition effective for treating a disease state comprising an administerable admixture of an effective amount of a therapeutic compound capable of altering nucleic acid  
10 sequence function and an effective amount of a surface active nonionic block copolymer having the following general formula:



15 wherein a is an integer such that the hydrophobe represented by  $(\text{C}_3\text{H}_6\text{O})$  has a molecular weight of approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an  
20 integer such that the hydrophile portion represented by  $(\text{C}_2\text{H}_4\text{O})$  constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 20%.

A particularly useful composition is an admixture  
25 of a compound capable of altering gene expression and/or protein translation, such as an antisense oligonucleotide, a triplex DNA compound, a ribozyme or other compound capable of altering nucleic acid sequence function, and the above-described nonionic block copolymer.

30 The composition of the present invention can be administered by a number of routes including, but not limited to topical, transdermal, oral, trans-mucosal, subcutaneous injection, intravenous injection, intraperitoneal injection and intramuscular injection.

35 Accordingly, an object of the invention is to provide a therapeutic drug delivery vehicle.



- 7 -

5 Another object of the present invention is to provide compositions that facilitate delivery of one or more therapeutic nucleic acid sequence function altering agents into the interior of a cell, such as a phagocytic cell, when admixed with a therapeutic agent.

Another object of the present invention is to provide compositions that act synergistically with a delivered agent once inside a cell.

10 Still another object of the invention is to provide nonionic block copolymers having surfactant properties that facilitate the transmission and introduction across cellular plasma membranes of nucleic acid sequences and compounds capable of altering nucleic acid sequence function.

15 A further object of the present invention is to provide compositions and a method for treating genetic and physiologic disorders using nucleic acid sequences and antisense oligonucleotides in combination with nonionic block copolymers.

20 Another object of the present invention is to provide compositions and a method useful for manipulating the expression of genes using triplex DNA compounds.

Yet another object of the invention is to provide DNA vaccines.

25 It is an object of the present invention to provide compositions which can be used to treat persons with infectious diseases.

Yet another object of the present invention is to provide a method of treating viral infections in humans or animals.

30 Another object of the present invention is a compound and method that is effective in inhibiting the replication of viruses in both animals and humans.

35 Another object of the present invention is to provide a compound and method that is effective in inhibiting the replication of HIV and other RNA and DNA viruses.

- 8 -

Yet another object of the present invention is to provide a method of treating microbial infections in humans or animals.

5 It is another object of the present invention to inactivate virus in a blood product prior to infusion into a person or animal.

10 These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiment and the appended claims.

### Brief Description of the Drawings

15 Fig. 1 is a grid illustrating block copolymers by molecular weight of hydrophobe and percent hydrophile.

Fig. 2 is a grid illustrating preferred therapeutic delivery block copolymers by molecular weight of hydrophobe and percent hydrophile.

20 Fig. 3 is a grid illustrating more preferred therapeutic delivery block copolymers by molecular weight of hydrophobe and percent hydrophile.

### Detailed Description

25 The present invention includes gene therapy compositions that are admixtures of a nonionic block copolymer and nucleic acid sequences or compounds capable of altering nucleic acid sequence function, and methods of delivering these compositions to a human or animal in need thereof for the intracellular alteration of gene expression and/or protein translation. It has been unexpectedly found that high  
30 molecular weight surface active nonionic polyoxyethylene-polyoxypropylene block copolymers having a low percentage of polyoxyethylene facilitate the transport of DNA and other compounds into cells and thus are useful for the intracellular delivery of therapeutic agents *in vivo* for the treatment of  
35 disease. It is believed that the block copolymers are particularly

- 9 -

useful in helping to reseal membranes and thus increase the percent survival of cells wherein nucleic acid sequences or other compounds have been intracellularly introduced. Surprisingly, it has also been found that compositions comprising the nonionic block copolymers of the present invention and nucleic acid sequences are less susceptible to the degrading effects of DNAase than nucleic acid sequences alone.

The present invention also comprises therapeutic compositions and methods which kill or inhibit the growth of microorganisms and alter the expression or function nucleic acid sequences. An example of the bacteria that the present invention is effective against is mycobacteria species, such as *Mycobacterium tuberculosis*, *Mycobacterium avium*, and *Mycobacterium leprae*. Other microorganisms that the invention is effective against include, but are not limited to, *Chlamydia trachomatis*, *Chlamydia pneumoniae*, *Listeria monocytogenes*, *Candida albicans*, *Cryptococcus neoformans*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Herpes simplex virus* type 1, *Cytomegalovirus*, influenza virus type A and B, and respiratory syncytial virus.

The present invention includes therapeutic compositions and methods for treating DNA viruses and RNA viruses, and infections and infectious diseases caused by such viruses in a human or animal, including infections caused by HIV or herpes or antigenically-related strains thereof. Antigenically-related strains are strains that cross react with antibodies specific for HIV. One skilled in the art can readily determine viral strains that are antigenically-related to HIV by conducting standard immunoassay tests using anti-HIV antibodies and the viral strain to be analyzed, and looking for positive cross-reactivity. The therapeutic compositions comprising the surface active copolymers disclosed herein are effective in inhibiting or suppressing the replication of such viruses in cells.

- 10 -

The present invention includes a therapeutic composition useful for delivering antimicrobial drugs and treating disease states comprising an admixture of a surface active nonionic block copolymer, a compound capable of altering nucleic acid sequence function, and an antibiotic or therapeutic drug. Examples of such compounds capable of altering nucleic acid sequence function include genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, and ribozymes. Drugs that can be used with the nonionic copolymers of the present invention include, but are not limited to, rifampin, isoniazid, ethambutol, gentamicin, tetracycline, erythromycin, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones such as ofloxacin and sparfloxacin, azithromycin, clarithromycin, dapsone, doxycycline, ciprofloxacin, ampicillin, amphotericin B, fluconazole, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, azithromycin, paromycin, diclazaril, clarithromycin, atovaquone, pentamidine, acyclovir, trifluorouridine, AZT, DDI, DDC, and other antiviral nucleoside analogs, foscarnat, ganciclovir, viral protease inhibitors, antisense and other modified oligonucleotides, and ribavirin.

Preferred drugs to use for various infectious microorganisms are listed in Table I.

Table I

<u>Organism</u>	<u>Drugs</u>
<u>Bacteria</u>	
Mycobacterium tuberculosis	Isoniazid, rifampin, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones such as ofloxacin and sparfloxacin

- 11 -

Table I (continued)

	<u>Organism</u>	<u>Drugs</u>
5	<i>Mycobacterium avium</i>	Rifabutin, rifampin, azithromycin, clarithromycin, fluoroquinolones
10	<i>Mycobacterium leprae</i>	Dapsone
	<i>Chlamydia trachomatis</i>	Tetracycline, doxycycline, erythromycin, ciprofloxacin
15	<i>Chlamydia pneumoniae</i>	Doxycycline, erythromycin
	<i>Listeria monocytogenes</i>	Ampicillin
	<u>Fungi</u>	
20	<i>Candida albicans</i>	Amphotericin B, ketoconazole, fluconazole
	<i>Cryptococcus neoformans</i>	Amphotericin B, ketoconazole, fluconazole
25	<u>Protozoa</u>	
	<i>Toxoplasma gondii</i>	Pyrimethamine, sulfadiazine, clindamycin, azithromycin, clarithromycin, atovaquone
30	<i>Pneumocystis carinii</i>	Pentamidine, atovaquone
35	<i>Cryptosporidium</i> sp.	Paromomycin, diclazaril
	<u>Virus</u>	
40	Herpes simplex virus type 1 and type 2	Acyclovir, trifluorouridine and other antiviral nucleoside analogs, foscarnat, antisense oligonucleotides, and triplex-specific DNA sequences
45	Cytomegalovirus	Foscarnet, ganciclovir
	HIV	AZT, DDI, DDC, foscarnat, viral protease inhibitors, peptides, antisense oligonucleotides, triplex and other nucleic acid sequences
50		

- 12 -

Table I (continued)

5	<u>Organism</u>	<u>Drugs</u>
	Influenza virus type A and B	Ribavirin
	Respiratory syncytial virus	Ribavirin
10	Varizella zoster virus	Acyclovir

15      Optionally, surfactants and low molecular weight  
 alcohols are added to the therapeutic admixture of antimicrobial  
 drug and nonionic block copolymer. Examples of surfactants  
 useful in the present invention include Tween 80 and emulsions  
 with fatty acids such as phospholipids, cholate and amino acids.  
 The preferred surfactant is Tween 80. Surfactants are added to  
 20      the admixture at a concentration ranging from approximately  
 0.1% to approximately 5% v/v. The preferred surfactant  
 concentration is approximately 2%. The term "approximately"  
 as it applies to concentrations expressed herein means the stated  
 concentration plus or minus ten percent. The term "low  
 25      molecular weight alcohols" means alcohols having two to eight  
 carbons. An example of a low molecular weight alcohols useful  
 in the present invention is ethanol, which is the preferred low  
 molecular weight alcohol. Low molecular weight alcohols are  
 added to the admixture at a concentration ranging from  
 30      approximately 0.5% to approximately 5% v/v. The preferred  
 low molecular weight alcohol concentration is between  
 approximately 1% and approximately 3% v/v.


35      The present invention also includes compositions  
 and methods for immunizing animals or humans, otherwise  
 termed DNA vaccination. Immunization is accomplished by  
 administering a composition comprising the gene that codes for  
 the gene product to be immunized against contained in an  
 expression, in combination with a block copolymer that  
 promotes and facilitates uptake of genetic material across cell

- 13 -

membranes. The introduced gene is expressed, resulting in the production of an antigenic gene product.


Still further, compositions comprising nonionic block copolymers and genes that code for compounds effective for killing, reducing or retarding cancer, such as lymphokines, may be administered to humans or animals for the treatment of cancer.

The present invention comprises a surface active copolymer that is preferably an ethylene oxide-propylene oxide condensation product with the following general formula:



wherein a is an integer such that the hydrophobe represented by  $(\text{C}_3\text{H}_6\text{O})$  has a molecular weight of between approximately 750 and approximately 15,000, and b is an integer such that the hydrophile portion represented by  $(\text{C}_2\text{H}_4\text{O})$  constitutes approximately 1% to approximately 50% by weight of the compound.

The present invention also comprises a therapeutic delivery composition useful for altering gene expression and/or protein translation comprising an administerable admixture of an effective amount of an anti-sense oligonucleotide or other nucleic acid sequence, and an effective amount of a nonionic block copolymer having the following general formula:




wherein a is an integer such that the hydrophobe represented by  $(\text{C}_3\text{H}_6\text{O})$  has a molecular weight of approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by  $(\text{C}_2\text{H}_4\text{O})$  constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to

- 14 -

approximately 20%. The term admixture as used herein means any combination of therapeutic drug and nonionic block copolymer, including solutions, suspensions, or encapsulations of drug in copolymer micelles. An effective amount is an amount sufficient to alter the activity and/or the amount of gene product produced by the gene or genes sought to be modulated in a human or animal.

The present invention also comprises a therapeutic delivery composition useful for immunizing an animal or human against a particular gene product comprising an administerable admixture of an effective amount of an expression vector, the gene that codes for the gene product to be immunized against contained in the expression vector, and an effective amount of a nonionic block copolymer having the following general formula:



wherein a is an integer such that the hydrophobe represented by  $(\text{C}_3\text{H}_6\text{O})_a$  has a molecular weight of approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by  $(\text{C}_2\text{H}_4\text{O})_b$  constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 20%. An effective amount is an amount sufficient to elicit an immunological response against the gene product of the nucleic acid sequence administered to the human or animal.

It should be understood that the molecular weight and percentage ranges that are described for the block copolymer are to be considered outside ranges and that any population of molecules that falls within the stated ranges is considered an embodiment of the present invention.



- 15 -

5 The entire block copolymer molecule is poorly soluble in water and is substantially nonionic. The steric configurations and physiochemical properties of the molecule, rather than the chemical nature of the constituent parts, are believed to be largely responsible for the antiinfective activity and therapeutic delivery activity. Compositions of the present invention include, but are not limited to aqueous solutions, suspensions or emulsions, such as oil-in-water emulsions.

10 The polymer blocks are formed by condensation of ethylene oxide and propylene oxide, at elevated temperature and pressure, in the presence of a catalyst. There is some statistical variation in the number of monomer units which combine to form a polymer chain in each copolymer. The molecular weights given are approximations of the average weight of copolymer molecule in each preparation and are dependent on the assay methodology and calibration standards used. It is to be understood that the blocks of propylene oxide and ethylene oxide do not have to be pure. Small amounts of other materials can be admixed so long as the overall physical chemical properties are not substantially changed. A more detailed discussion of the preparation of these products is found in U.S. Patent No. 2,674,619, which is incorporated herein by reference in its entirety.

25 Ethylene oxide-propylene oxide condensation products which may be employed in the present invention are summarized in Table II. It is to be understood that these compounds are merely representative of the compounds that can be used to practice the present invention and do not include all possible compounds that could be used to practice the present invention. The high molecular weight copolymers listed in Table II that do not have a BASF tradename are novel compositions that have never been synthesized before.

30

- 16 -

Table II

CRL #	Poloxamer	BASF Trade Name	Molecular Weight of POP	% POE
	122	L42	≈1200	≈20%
CRL-85171	181	L61	≈1750	≈10%
CRL-85172	182	L62	≈1750	≈20%
CRL-85173	183	L63	≈1750	≈30%
CRL-85174	184	L64	≈1750	≈40%
CRL-85175	185	P65	≈1750	≈50%
CRL-85178	188	F68	≈1750	≈80%
CRL-85202	212	L72	≈2050	≈20%
CRL-85221	231	L81	≈2250	≈10%
CRL-8122	282	L92	≈2750	≈20%
CRL-8131	331	L101	≈3250	≈10%
CRL-8133	333	P103	≈3250	≈30%
CRL-8135	335	P105	≈3250	≈50%
CRL-9038	338	F108	≈3250	≈80%
CRL-8141	401	L121	≈4000	≈10%
CRL-8142	402	L122	≈4000	≈20%
CRL-8143	403	P123	≈4000	≈30%
CRL-8941	441	L141	≈4400	≈10%
CRL-8950	-----	-----	≈6000	≈5%
CRL-1235	-----	-----	≈7500	≈5%
CRL-1190	-----	-----	≈10,000	≈5%
CRL-336	-----	-----	≈14,000	≈5%
CRL-1183	-----	-----	≈3750	≈10%
CRL-1122	-----	-----	≈5900	≈12%
CRL-3362	-----	-----	≈3900	≈11%
CRL-3632	-----	-----	≈4740	≈11%
CRL-9352	-----	-----	≈7750	≈15%
CRL-1187	-----	-----	≈750	≈25%

- 17 -

5 A grid illustrating the range of copolymer encompassed by the present invention based upon the molecular weight of the hydrophobe portion and the percent hydrophile, and showing selected nonionic block copolymers appears as Figure 1. The polymer blocks are formed by condensation, at elevated temperature and pressure, of ethylene oxide and propylene oxide in the presence of a catalyst. There is some statistical variation in the number of monomer units which combine to form a polymer chain in each copolymer. The molecular weights given are approximations of the average size of copolymer molecules in each preparation. A further description of the preparation of these block copolymers is found in U.S. Patent No. 2,674,619. (Also see, "A Review of Block Polymer Surfactants", Schmolka I.R., *J. Am. Oil Chemist Soc.*, 54:110-116 (1977) and *Block and Graft Copolymerization*, Volume 2, edited by R.J. Ceresa, John Wiley and Sons, New York, 1976.

10 It has been discovered that the copolymers particularly effective as therapeutic delivery agents are shown in Figures 2 and 3. As is apparent from Figures 2 and 3, the copolymers most effective as therapeutic delivery agents are high molecular weight and have low percentages of POE - generally less than 20% POE.

25 Non-ionic block copolymers form micelles above their critical micelle concentration. The non-ionic copolymers have negative thermal coefficients of solubility. In the cold, the kinetic energy of water molecules is reduced and they form weak hydrogen bonds with the oxygen of the POP blocks. This hydration of the hydrophobe promotes solubility at low temperatures. As the temperature rises, the "cloud point" is reached; the increased kinetic energy of the water breaks the hydrogen bonds, the polymer becomes insoluble and micelles form.

- 18 -

Thus, the copolymers, which are therapeutic themselves, can form physical structures that can be combined or loaded with an additional, distinct therapeutic agent. Consequently, the nonionic block copolymers of the present invention can be used as therapeutic drug delivery vehicles. Admixtures of therapeutic drugs with non-ionic block copolymers have the advantage of synergistic activity of two therapeutic agents. Further, copolymers having specific characteristics can be selected for use with particular therapeutic drugs. For example, CRL-8131, which is hydrophobic, is an excellent carrier for hydrophobic antibiotics such as rifampin. However, other agents which are not distinctly hydrophobic can be used according to the present invention.

A therapeutic delivery vehicle is prepared using any of the surface active nonionic block copolymers of the present invention in combination with any of a variety of antimicrobial agents. In a one embodiment CRL-8131 is used at a concentration of approximately 3% to approximately 5% to construct a therapeutic delivery vehicle. Therapeutic delivery vehicles made using copolymers that are more hydrophilic than CRL-8131 normally require a higher concentration (approximately 5% to approximately 10%) of the copolymer.

Using copolymer-based micelles as a therapeutic drug delivery vehicle is particularly desirable because the micelles are accumulated readily and are present for an extended period of time, in macrophages, the site of HIV and other viral infections and a major target for viral therapy. Examples of such therapeutic copolymer-based therapeutic compositions include CRL-8131 combined with 2% Tween 80 and 1% ethanol, and CRL-8142 combined with 1% Tween 80 and 5% ethanol.

Nucleic acid sequences or other compounds capable of altering nucleic acid sequence function are administered to a human or animal to alter gene expression

- 19 -

and/or modify the amount or activity of gene product. For example, antisense oligonucleotides admixed with the above-described nonionic block copolymers yield compositions useful for delivery of the antisense oligonucleotides for the purpose of altering or regulating gene expression and/or protein translation. Further, nucleic acid sequences such as genes can be administered which incorporate into the chromosome replacing or augmenting the defective gene. Alternatively, the intracellularly administered gene may reside in the cell and be expressed in an extrachromosomal element.

The present invention also provides novel compositions and methods for immunizing an animal or human. The compositions comprise an expression vector, a gene that codes for the gene product to be immunized against contained in the expression vector, and a block copolymer effective for transferring genetic material such as expression vectors across the membrane of cells. The method of immunizing an animal or human comprises administering of the expression vector-containing copolymer composition to the animal or human. A preferred mode of administration is by intraperitoneal injection. This embodiment of the invention provides means for the delivery of genetic sequences capable of expressing an antigenic gene product directly into human or animal cells, either *in vivo* or *ex vivo* with subsequent reintroduction into the human or animal. Once introduced into the cells the production of antigenic gene product induces and maintains an immune response by the human or animal against the introduced gene product.

The following specific examples illustrate various aspects of the invention, such as compositions and methods of the invention useful for gene therapy, and compositions and methods of the invention useful for gene-mediated immunization. It should be appreciated that other embodiments and uses will be apparent to those skilled in the art and that the invention is not limited to these specific illustrative examples.

- 20 -

## Example I

A therapeutic delivery vehicle is prepared by combining any of the surface active nonionic block copolymers, such as CRL-8131 with any of a variety of compounds capable of altering nucleic acid sequence function. For CRL-8131 a concentration of three to five percent weight per volume is desirable to construct the therapeutic vehicle. For more hydrophilic copolymer a five to ten percent weight per volume.

300 milligrams of CRL-8131 was added to 10 ml of 0.9% NaCl and the mixture is solubilized by storage at temperatures of 2-4°C until a clear solution is formed. An appropriate amount of a compound capable of altering nucleic acid gene function is added to the mixture and micelles associating the copolymer and the compound are formed by raising the temperature above 5°C and allowing the suspension of micelles to equilibrate. The equilibrated suspension is suitable for administration.

For example, an antisense oligonucleotide sequence, such as one of those disclosed by Matsukara, M. et al. *Proc. Natl. Acad. Sci. USA* 84:7706-7710 (1987), which is expressly incorporated herein in its entirety by reference, is combined with the copolymer to form a micelle composition.

Briefly, phosphorothioate or methylphosphonate derivatives of a sequence complimentary to regions of the *art/trs* genes of HIV having the sequence 5'-TCGTCGCTGTCTCG-3' are prepared according to the method of Matsukura et al. 300 milligrams of CRL-8131 is added to 10 ml of 0.9% NaCl and the mixture is solubilized by storage at temperatures of 2-4°C until a clear solution is formed. The desired antisense oligonucleotide subsequently is mixed with the copolymer solution to provide a concentration effective in inhibiting viral activity when administered to a patient infected with the HIV virus. Generally the effective amount of antisense compound will be such that the final concentration in the blood

- 21 -

is in the range of 1  $\mu$ M to 100  $\mu$ M, although other effective amounts of antisense compounds outside this range may be found for specific antisense compounds. One skilled in the art can readily test the relative effectiveness of any particular antisense oligonucleotide according to the *in vivo* test of Matsukura, et al.

An average person has approximately 6.25 liters of blood. Thus, oligonucleotide concentrations of approximately 6 mM to 600 mM are required in the composition when 1 ml injections are to be administered. Lower oligonucleotide compositions can be used with larger administration volumes.

### Example II

The antiinfective antisense oligonucleotide composition of Example I is administered to HIV patients by any route effective to reduce viral activity. The preferred route of administration is by intravenous injection. The antisense composition may be administered multiple times a day to ensure that an effective amount of the antisense oligonucleotide is maintained.

### Example III

A gene therapy composition for treating an animal or human suffering from the effects of a defective or missing gene is made by combining a copolymer, such as CRL-8131 with a normal copy of the defective gene. For example, for patients suffering from adenosine deaminase (ADA) deficiency a gene therapy composition is made that contains a normal copy of the adenosine deaminase gene. The gene therapy composition is made by mixing a copolymer prepared as described above in Example I with the desired gene, removing blood from the human or animal, transfecting blood cells with the ADA gene-containing composition, and reintroducing the transfected blood cells into the human or animal. The

- 22 -

introduced gene is expressed *in vivo*, alleviating the effects of the original gene deficiency.

#### Example IV

5 Similarly, the gene therapy composition of Example III is combined with isolated T-lymphocytes to form T-lymphocytes containing the ADA gene. The ADA gene-containing T-lymphocytes are subsequently administered, for example by injection, into the patient suffering from adenosine deaminase deficiency. The administered cells express the ADA and produce adenosine deaminase, thus augmenting the supply of the enzyme in the patient and correcting the deficiency.

#### Example V

15 DNA vaccination is carried out essentially as described for gene therapy in Examples III or IV, except that the gene that is introduced into the host expresses an antigenic gene product that is recognized as foreign by the host animal, thus eliciting an immune response.

#### Example VI

A composition comprising copolymer CRL-8131 and an expression vector containing the gD gene of *Herpes simplex* virus type-1 was used in a transfection experiment. DNA transfection normally is performed using standard calcium chloride and DEAE dextran precipitation techniques. DEAE dextran is used to rough up the cell membrane and calcium is used to precipitate DNA onto the cell surface, facilitating DNA uptake into the cells. This procedure is generally toxic to the cells, however, and causes substantial cellular mortality.

25 30 A new transfection system was discovered using the block copolymer of the present invention in place of calcium chloride. In fact, it was surprisingly discovered that



- 23 -

copolymer assisted transfection occurs even in the absence of DEAE dextran.

Vero cells were incubated in DEAE dextran for 30 seconds. A mixture of copolymer and an expression vector containing glycoprotein gD DNA of *Herpes simplex* virus type-1 was added to Vero cells immediately after the removal of DEAE dextran. It was found that up to 40% of the cells were effectively transfected with the gD gene.

Surprisingly, in two out of four experiments copolymers were able to transfect Vero cells at a lower than 40% efficiency even when the DEAE dextran incubation step is omitted.

#### Example VII

Other studies have also demonstrated that block copolymers are effective in transferring genetic material across cellular membranes *in vivo*. DNA vaccine-induced immunization was successful when an expression vector containing the gD gene of *Herpes simplex* virus type-1 combined with copolymer was injected intraperitoneally into rabbits every two weeks. Sera was collected and tested for the presence of anti-gD antibody. Low levels of anti-gD antibody were detected after 4 weeks of inoculation in this fashion. These results demonstrate that genetic material administered intraperitoneally with a copolymer delivery vehicle is taken up by cells *in vivo* and expressed to give the gene product in quantities sufficient to elicit an immune response.

#### Example VIII

**DNase protection experiments.** Five different compounds (CRL 1122, 3362, 3632, 9352, and 8131) were used in experiments to test the degree of protection. DNA was mixed with compounds at 4°C, and after 15 min. at 37°C DNase I (1 µl of 10 mg/ml solution) was added. After 30 min. of incubation at 37°C, DNase I was removed by treatment with

- 24 -

proteinase K (3  $\mu$ l of 10 mg/ml solution). Controls were: DNase I in the absence of nonionic block copolymer and DNA alone without any DNase I treatment.

5 DNA was protected from DNase I degradation in all samples in which nonionic block copolymers were present. The best protection of DNA was achieved with CRL-3362 and 8131. DNA copolymer compositions did not migrate in horizontal agarose electrophoresis and remained within the wells (stained with ethidium bromide). Effective protection  
10 against DNase I action was achieved in solutions of 1 volume DNA solution (1  $\mu$ g/ml) to 5 volumes of nonionic block copolymer (30  $\mu$ g/ml). The estimated amount of protection varied from experiment to experiment and was estimated to be within 15-40% of total DNA.

15 Additional experiments showed that DNA-copolymer compounds failed to transform *E. coli* competent cells via the calcium method. Phenol also failed to dissolve nonionic block copolymer away from DNA. DNA bound to NBC can be precipitated by adding 5 volumes of isopropyl  
20 alcohol.

### Example IX

Transfection experiments. Typical transfection experiments for transient expression of herpes viral glycoprotein genes and other genes of interest involved the  
25 following procedure. Cells such as COS (African monkey kidney cells; CV1) are seeded on 6-well plates. Transfection is performed when cells are 50-80% confluent (still in log growth phase). Cells are first washed with PBS buffer, they are  
30 incubated with 0.5 ml of DEAE-Dextran solution (500 mg/ml) for 1-2 minutes, this solution is aspirated and DNA precipitate is added to cells. DNA to be transfected is mixed for 30 min. at room temperature with  $\text{CaCl}_2$  at controlled pH conditions to form a fine precipitate. This solution is mixed with 1 ml of  
35 growth medium (DMEM) and put onto cells for 4 hours at

- 25 -

37°C. At this time, the cells are shocked with 15% glycerol and subsequently washed with PBS. This osmotic shock facilitates the taking up of  $\text{CaCl}_2$ -DNA precipitate into cells. Cells are then washed again with PBS, and incubated with growth media at 37°C for 48 hours.

Gene expression is detected in most cases using specific monoclonal antibodies directed against the expressed proteins using indirect immunofluorescence. The expressed proteins can be also labeled with radioactive tracers and immunoprecipitated or detected in westerns.

25  $\mu\text{l}$  of DNA (7  $\mu\text{g}$ ) and 25  $\mu\text{l}$  of nonionic block copolymer (30  $\mu\text{g}/\text{ml}$ ) were used. Additionally, mixing of nonionic block copolymer with DNA on ice, and addition of mixture into the cells produced similar results as when they were added separately (DNA added first and nonionic block copolymer second).

Copolymers 1183, 1187, 8131, 1235, 8950AQ and 1190AQ (where AQ indicates that the nonionic block copolymers were diluted 1:10 and 25  $\mu\text{l}$  were used). Typical results are as follows. Transfection with DNA alone, dextran alone, copolymer alone, and DNA plus dextran had negligible transfection of less than 0.2%. In contrast, the positive control of DNA plus dextran plus glycerol has transfection of 2% while various copolymers plus DNA were successful in transfecting DNA into cells up to 2.5 times better than the control, as shown in Table III:

- 26 -

Table III

Copolymer	Percent Transfection
1183	2%
1187	5%
8131	2%
1235	3%
8950AQ	4%
1190AQ	5%


5                    There was no copolymer associated toxicity  
except mild toxicity with 1187. The others were toxic  
especially after glycerol treatment.

10                   It should be understood that the foregoing relates  
only to preferred embodiments of the present invention and that  
numerous modifications and alterations may be made without  
departing from the spirit and scope of the invention as set forth  
in the appended claims.

- 27 -

We claim:

1. A therapeutic composition for treating a human or animal comprising,  
5 a compound capable of altering nucleic acid function admixed with a nonionic block copolymer, wherein the block copolymer has the following formula:



10 wherein the molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 750 and 15,000 and the molecular weight represented by the polyoxyethylene portion of the copolymer  
15 constitutes between approximately 1% and 50% of the copolymer.

2. The composition of Claim 1 wherein the  
20 molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 2,250 and 15,000 and the molecular weight represented by the polyoxyethylene portion of the copolymer constitutes between approximately 5% and 20% of the copolymer.

25 3. The composition of Claim 1 wherein the molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 3,250 and 15,000 and the molecular weight represented by the polyoxyethylene  
30 portion of the copolymer constitutes between approximately 5% and 20% of the copolymer.

4. The composition of Claim 1 wherein the copolymer is CRL-8131 or CRL-8142.

- 28 -

5           5.    The composition of Claim 1 wherein the compound capable of altering nucleic acid sequence function is selected from the group consisting of genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, and ribozymes.

10           6.    The composition of Claim 7 further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of an low molecular weight alcohol.

            7.    The composition of Claim 6 wherein the surfactant is Tween 80 and the alcohol is ethanol.


15           8.    The composition of Claim 7 further comprising an expression vector, wherein the compound capable of altering nucleic acid sequence function is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.

20

- 29 -

9. A method of delivering a compound capable of altering nucleic acid sequence function to a human or animal comprising,

the step of administering to a human or animal a composition comprising a compound capable of altering nucleic acid sequence function admixed with a nonionic block copolymer, wherein the block copolymer has the following formula:



wherein the molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 750 and 15,000 and the molecular weight represented by the polyoxyethylene portion of the copolymer constitutes between approximately 1% and 50% of the copolymer.

10. The method of Claim 9 wherein the molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 2,250 and 15,000 and the molecular weight represented by the polyoxyethylene portion of the copolymer constitutes between approximately 5% and 20% of the copolymer.

11. The method of Claim 9 wherein the molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 3,250 and 15,000 and the molecular weight represented by the polyoxyethylene portion of the copolymer constitutes between approximately 5% and 20% of the copolymer.

12. The method of Claim 9 wherein the copolymer is CRL-8131 or CRL-8142.

- 30 -

13. The method of Claim 9 wherein the compound capable of altering nucleic acid sequence function is selected from the group consisting of genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, and ribozymes.

14. The method of Claim 9 further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of a low molecular weight alcohol.

15. The method of Claim 14 wherein the surfactant is Tween 80 and the alcohol is ethanol.

16. The method of Claim 9 further comprising an expression vector, wherein the compound capable of altering nucleic acid sequence function is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.



1/3




FIGURE 1

2/3




FIGURE 2

3/3




FIGURE 3

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/11594

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/00

US CL :424/78.08, 94.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/78.08, 94.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,869,900 (POZZI ET AL.) 26 September 1989, see column 2.	1-16
Y	US, A, 5,037,644 (SHAKED ET AL.) 06 August 1991, see columns 7, 8, 9.	1-16
Y	US, A, 5,221,495 (CAO) 22 June 1993, see columns 7, 8, 9.	1-16
Y	WO, A, WO 87/06831 (EMORY UNIVERSITY) 19 November 1987, see claims.	1-16

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

28 DECEMBER 1994

Date of mailing of the international search report

21 FEB 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PETER KULKOSKY

Telephone No. (703) 308-2351